**Agents:** Cholecystokinin  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Mice;  
**Pump:** Not Stated;  
**Duration:** 4 weeks;  
**ALZET Comments:** Dose (1 ug/kg/hr or 5 ug/kg/hr); 0.9% Saline used; Controls received mp w/ vehicle; animal info (Male); Cholecystokinin aka CCK; diabetes; 

**Agents:** Amylin, Cholecystokinin-8, AC3174, AC170236, AC170222  
**Vehicle:** DMSO, water;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** Not Stated;  
**Duration:** 14 or 28 days;  
**ALZET Comments:** Controls received mp w/ vehicle; animal info (Diet-induced Obese Rats); functionality of mp verified by plasma levels; Vehicle was 50% DMSO:50% water; Multiple pumps per animal (2); AC170236 is a CCK2R-selective agonist; Therapeutic indication (Obesity); Dose: amylin (50 μg/kg/day), AC3174 (10 μg/kg/day), CCK-8 (100 μg/kg/day); 

**Agents:** Cholecystokinin octapeptide  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** Not Stated;  
**Duration:** 8 weeks;  
**ALZET Comments:** Controls received mp w/ vehicle; animal info (Sprague Dawley, male, 6 wks old, STZ induced diabetes); pumps replaced after 4 weeks; peptides; cholecystokinin octapeptide also known as CCK-8S; long-term study; 

**Agents:** Cholecystokinin-8S; cholecystokinin-8; gastrin-17  
**Vehicle:** Not Stated;  
**Route:** SC;  
**Species:** Mice;  
**Duration:** 2,6 days;  
**ALZET Comments:** Comparison of single SC gastrin-17 injection vs. mp; peptides; mp incubated overnight in 0.9% NaCl at room temperature prior to implantation; 

**Agents:** Cholecystokinin-8 Vehicle: Saline;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** 1003D;  
**Duration:** 72,74 hours;  
**ALZET Comments:** Peptides; 

**Agents:** Cholecystokinin Vehicle: Not Stated;  
**Route:** Not Stated;  
**Species:** Not Stated;  
**Pump:** Not Stated;  
**Duration:** Not Stated;  
**ALZET Comments:** Peptides; review article: pump mentioned on p. 399; 

**Agents:** Cholecystokinin-8S Vehicle: BSA;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** 2001;  
**Duration:** 4 days;  
**ALZET Comments:** Controls received mp w/ vehicle; functionality of mp verified by CCK plasma levels by RIA; comparison of intermittent injections vs. SC infusion via mp; peptides; 

**Agents:** Transforming growth factor-a; Brain-derived neurotrophic factor; Vasoactive intestinal polypeptide; Peptide, histidine-isoleucine; Gastrin releasing peptide; Substance P; Neuregulin-1; Neuropeptide Y; Somatostatin; Antrin; Cholecystokinin; Thyrotropin-releasing hormone; Neurotensin; Neuregulin N; Vehicle: CSF, artificial;  
**Route:** CSF/CNS (third ventricle);  
**Species:** Hamster;  
**Pump:** 2002;  
**Duration:** 18,22 days;  
**ALZET Comments:** Peptides
P4796: M. Covasa, et al. Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokinin. American Journal of Physiology Regulatory, Integrative, and Comparable Physiology 2001;280(R331-R337
 Agents: Cholecystokinin-8 Vehicle: Saline; Route: IP; Species: Rat; Pump: 2004; Duration: 28 days;
ALZET Comments: Controls received mp w/ vehicle; comparison of IP injections vs. mp; peptides

 Agents: Cholecystokinin-8S; Devazepide Vehicle: Albumin, bovine serum; DMSO; Route: SC; Species: Rat; Pump: 2001; 2002; 2ML2; 1003D; Duration: 36 hours, 3, 7, 28 days;
ALZET Comments: controls received mp w/ saline or DMSO; peptides

 Agents: Cholecystokinin-8; Devazepide; Cholecystokinin-8S Vehicle: DMSO; Albumin, bovine serum; Route: SC; Species: Rat; Pump: 2001; 2002; Duration: 3, 7, 28 days; 36 hrs;
ALZET Comments: controls received mp w/NaCl or DMSO; pumps replaced after 14 days; peptides

 Agents: Cholecystokinin-8 Vehicle: Saline, physiological; Route: IP; CSF/CNS; Species: Rat (pregnant); Pump: 2001; Duration: Not Stated;
ALZET Comments: Controls received saline; peptides; non-pregnant rats were ovariectomized

 Agents: Cholecystokinin-8; cholecystokinin-4; cholecystokinin-4 analogs Vehicle: Not Stated; Route: IP; Species: Mice; Pump: 2001; Duration: 8 days;
ALZET Comments: Controls received no surgery or mp with saline; functionality of mp verified by residual volume; peptides

 Agents: Cholecystokinin-8; MK-329 Vehicle: Albumin; Saline; DMSO; Route: SC; Species: Rat; Pump: 2002; Duration: 7 weeks, 4,7 hours;
ALZET Comments: Long-term study, pumps replaced every 10th day; peptides; devazepide is L-364, 718 or MK-329 and is a CCK-A receptor antagonist

 Agents: MK-329; Cholecystokinin 8-sulfate Vehicle: DMSO; Water; Albumin, bovine serum; Saline; Route: SC; Species: Rat; Pump: 2002; Duration: 7 weeks, 4,7 hours;
ALZET Comments: Long-term study, pumps replaced every 10th day; peptides; devazepide is L-364, 718 or MK-329 and is a CCK-A receptor antagonist

 Agents: Gastrin; Pentagastrin; Cholecystokinin-8S; Tiotidine Vehicle: Saline; Route: SC; Species: Guinea pig; Pump: 2001; Duration: 7 days;
ALZET Comments: peptides

 Agents: Cholecystokinin-8 Vehicle: Not Stated; Route: IP; Species: Not Stated; Pump: 2001; Duration: Not Stated;
ALZET Comments: Controls received mp with saline; comparison of injections vs. mp; peptides; infusion produced more physiological levels than did injection
Agents: Cholecystokinin antagonist Vehicle: DMSO; Water; Route: SC; Species: Guinea pig; Pump: 2001; Duration: 72 hours; ALZET Comments: agent is L364,718; 'L364,718 given an a constant infusion... successfully ameliorated the progression of acute 'traumatic pancreatitis.' (p. 56)

Agents: Cholecystokinin-8; L-364,718 Vehicle: Albumin, human serum; DMSO; Route: SC; Species: Rat; Pump: 2002; 2ML2; Duration: 7 weeks; ALZET Comments: controls received mp w/ DMSO only or no treatment; long-term study, pumps replaced every 12 days; peptides; 80% DMSO used; L-364,718 is a CCK antagonist; 2 mps used - one with CCK, one with L364,718

Agents: Atrial natriuretic factor; cholecystokinin; Granulocyte-colony stimulating factor.; glucagon; insulin; interleukin-2; interleukin-3; melatonin; nerve growth factor; neurotensin; prolactin; theophylline Vehicle: Not Stated; Route: CSF/CNS; IA (femoral); intrasplenic; IP; SC; Species: Not Stated; Pump: Not Stated; Duration: Not Stated; ALZET Comments: Peptides; ALZA-authored, review of peptide delivery issues and applications; tissue perfusion (spleen)

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: IP; Species: Rat; Pump: 2001; Duration: Not Stated; ALZET Comments: Controls received mp with saline; peptides

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: CSF/CNS; Species: Rat; Pump: 2001; Duration: 8 days; ALZET Comments: peptides

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: IV (jugular); Species: Rat; Pump: 2001; Duration: 7 days; ALZET Comments: controls received mp w/ saline; 2 doses of agent infused; peptides

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: SC; Species: Rat; Pump: 2001; Duration: 7 days; ALZET Comments: controls received mp w/ saline; 2 doses of agent infused; peptides

Agents: Acetylcholine chloride; Cefalotin; Cholecystokinin tetrapeptide; Epinephrine HCl; Bombesin; Endorphin, B-; Enkephalin, methionine-; Norepinephrine HCl Vehicle: Saline; Sodium bisulfite; Route: CSF/CNS (hypothalamus); Species: Rat; Pump: 2002; Duration: 5, 20 weeks; ALZET Comments: Cholinergic agent; pumps replaced periodically; mp connected to perm. steel cannula in hypothalamus; cannula fitted w/removable protector; (see p.217); agents infused sep. (cefalotin infused w/each agent); long-term study; peptides

Agents: Cholecystokinin 8-sulfate Vehicle: Saline; Route: CSF/CNS; Species: Rat; Pump: 2001; Duration: 5 days; ALZET Comments: controls received mp w/ saline; study of effects of CCK on sleep; stability of CCK-8S verified; peptides
Agents: Cholecystokinin, glutaryl-; Cholecystokinin, pyroglutamyl-; Cholecystokinin octapeptide Vehicle: HCl; Saline; Sodium bicarbonate; Route: CSF/CNS (suprachiasmatic nucleus); Species: Rat; Pump: 1701; Duration: 7 days;
ALZET Comments: controls received mp w/saline; mp connected to catheter in SCN; peptides

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: CSF/CNS; Species: Rat; Pump: 2001; Duration: Not Stated;
ALZET Comments: mp connected to cannula in left ventricle; comparison of ICV injections via microsyringe vs. mp infusion; peptides

Agents: Cholecystokinin octapeptide; Glucagon Vehicle: Saline; Route: SC; Species: Rat; Pump: 2002; Duration: 14 days;
ALZET Comments: controls received mps w/ saline; peptides

Agents: Cholecystokinin-33 Vehicle: Water; Route: SC; Species: Rat; Pump: Not Stated; Duration: Not Stated;
ALZET Comments: 2 + 2 days; pump in 1 rat for 2 days, removed & implanted in 2nd rat for 2 days; peptides

Agents: Cholecystokinin 8-sulfate Vehicle: Saline; Route: IP; Species: Rat; Pump: 2001; 2002; Duration: 1, 2 weeks;
ALZET Comments: Peptides

Agents: Cholecystokinin octapeptide Vehicle: Saline; Route: SC; Species: Mice; Pump: 2002; Duration: 2, 7 days;
ALZET Comments: Peptides

Agents: Cholecystokinin Vehicle: Not Stated; Route: SC; Species: Rat; Pump: Not Stated; Duration: 2 days;
ALZET Comments: Preliminary experiment listed @end of Gen. Disc.; peptides